Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

608 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
5-Azacitidine has limited therapeutic activity in myelofibrosis.
Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A. Mesa RA, et al. Among authors: verstovsek s. Leukemia. 2009 Jan;23(1):180-2. doi: 10.1038/leu.2008.136. Epub 2008 May 29. Leukemia. 2009. PMID: 18509350 Clinical Trial. No abstract available.
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Giles FJ, et al. Among authors: verstovsek s. Leuk Res. 2005 Jun;29(6):649-52. doi: 10.1016/j.leukres.2004.11.013. Epub 2005 Apr 1. Leuk Res. 2005. PMID: 15863204 Clinical Trial.
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. Giles FJ, et al. Among authors: verstovsek s. Leuk Res. 2006 Jul;30(7):801-11. doi: 10.1016/j.leukres.2005.10.024. Epub 2005 Dec 5. Leuk Res. 2006. PMID: 16332390 Clinical Trial.
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD, Cooper M, Bilgrami SF, Ferrant A, Daenen S, Karsten V, Cahill A, Albitar M, Kantarjian H, O'Brien S, Feldman E. Giles F, et al. Among authors: verstovsek s. Leuk Res. 2006 Dec;30(12):1591-5. doi: 10.1016/j.leukres.2006.02.019. Epub 2006 Mar 29. Leuk Res. 2006. PMID: 16574225 Clinical Trial.
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Mesa RA, et al. Among authors: verstovsek s. Leuk Res. 2007 Jun;31(6):737-40. doi: 10.1016/j.leukres.2006.12.002. Epub 2007 Jan 8. Leuk Res. 2007. PMID: 17210175 Review.
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O'brien S, Giles FJ. Albitar M, et al. Among authors: verstovsek s. Leukemia. 2007 Mar;21(3):480-8. doi: 10.1038/sj.leu.2404506. Epub 2007 Jan 11. Leukemia. 2007. PMID: 17215857
608 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page